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Abstract 30 
Gliomas encompass highly invasive primary central nervous system (CNS) tumours of 31 
glial cell origin with an often-poor clinical prognosis. Of all gliomas, glioblastoma is the 32 
most aggressive form of primary brain cancer. Current treatments in glioblastoma are 33 
insufficient due to the invasive nature of brain tumour cells, which typically results in local 34 
tumour recurrence following treatment. The latter represents the most important cause 35 
of mortality in glioblastoma and underscores the necessity for an in-depth understanding 36 
of the underlying mechanisms. Interestingly, increased synthesis and secretion of 37 
several proteolytic enzymes within the tumour microenvironment, such as matrix 38 
metalloproteinases, lysosomal proteases, cathepsins and kallikreins for extracellular-39 
matrix component degradation may play a major role in the aforementioned glioblastoma 40 
invasion mechanisms. These proteolytic networks are key players in establishing and 41 
maintaining a tumour microenvironment that promotes tumour cell survival, proliferation, 42 
and migration. Indeed, the targeted inhibition of these proteolytic enzymes has been a 43 
promisingly useful therapeutic strategy for glioblastoma management in both preclinical 44 
and clinical development. We hereby summarize current advances on the biology of the 45 
glioblastoma tumour microenvironment, with a particular emphasis on the role of 46 
proteolytic enzyme families in glioblastoma invasion and progression, as well as on their 47 
subsequent prognostic value as biomarkers and their therapeutic targeting in the era of 48 
precision medicine.  49 
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Introduction 53 
Gliomas are central nervous system (CNS) tumours of glial cell-origin. Glioblastoma multiforme 54 
(GBM), or simply glioblastoma in particular, is the most advanced stage of gliomas and 55 
represents the most prevailing type of primary brain tumour in adults. Glioblastoma is 56 
characterized by high oxygen deprivation within the centre of the tumour mass leading to 57 
extensive necrosis, as well as high vascular proliferation and  increased infiltrative capacity of 58 
tumour cells [1]. Glioblastoma is also characterized by a diffuse infiltration of isolated cells 59 
migrating beyond the tumour margins. This renders surgical resection ineffective as these cells 60 
remain near the surgical margins and inexorably represent a major cause of recurrence after 61 
surgery. The current standard of care for glioblastoma consists of surgical resection of the 62 
tumour along with the combination of the alkylating agent Temozolomide as adjuvant 63 
chemotherapy and radiotherapy treatment. However, despite achieving surgical resection 64 
coupled to these follow-up treatment modalities in most tumours, the median survival of 65 
glioblastoma is currently only 15 months [2].  66 
Among a plethora of reported interactions [3] it has been well-established that both 67 
tumour and stromal cells in glioblastoma can interact within the tumour microenvironment 68 
(TME) via the expression of proteolytic enzymes (or proteases) that degrade the extracellular 69 
matrix (ECM) components, accounting for increased migration and aggressiveness. A number 70 
of proteases may play decisive roles in this process. The most relevant protease families in 71 
glioblastoma development/progression include the Metzincin superfamily of proteases [matrix 72 
metalloproteinases (MMPs) and Adamalysins]; the kallikrein-related peptidases (KLKs) and 73 
the lysosomal peptidases (cathepsins). Here we are focusing on these specific families of 74 
proteases as there have been many preclinical studies linking them to glioblastoma 75 
progression with a promise of translating such findings into clinical practice. Although multiple 76 
studies have attributed potential oncogenic roles to several peptidases belonging to the 77 
aforementioned families, a more in-depth understanding of their interplay and involvement in 78 
GBM progression is essential. To address this literature gap, herein, we provide a detailed 79 
overview of the invasive characteristics of the glioblastoma microenvironment in the context of 80 
extracellular proteolysis and further elaborate on existing preclinical and clinical evidence that 81 
examines the value of extracellular proteases as putative therapeutic targets and/or 82 
diagnostic/prognostic biomarkers.  83 
 84 
Glioblastoma: the most aggressive form of human gliomas 85 
Gliomas are a category of CNS tumours arising in the non-neural component of the brain, 86 
primarily occupied by glial cells. Glial cells are divided into three main populations: astrocytes 87 
(the most abundant cell type), oligodendrocytes, and microglial cells. Although gliomas may 88 
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theoretically arise from any of the above-mentioned glial cell populations, the vast majority is 89 
believed to arise from astrocytes and thus, are termed “astrocytomas”. The latter are classified 90 
into grades according to their histological characteristics: the non-malignant grades I (Pilocytic) 91 
and II (Low-grade, well-differentiated), and the malignant grades III (Anaplastic) and IV 92 
(Glioblastoma Multiforme) [4]. Glioblastoma multiforme (GBM) represents the most advanced 93 
stage of gliomas and the most common malignant brain tumour [4]. It mainly develops in the 94 
supra-tentorial region (brain hemispheres) of adult individuals and displays wide molecular and 95 
morphological heterogeneity [5-7]. In most cases, glioblastomas are considered as primary 96 
tumours, thus arising rapidly de novo without observing the development of premalignant 97 
grade I-III lesions. Secondary glioblastomas, which are associated with better survival, arise 98 
at a more stepwise fashion, such as from lower grade astrocytomas [8]. Histological hallmarks 99 
of glioblastoma include cellular atypia and anaplasia (cellular abnormality and 100 
dedifferentiation), increased cell density, areas of necrosis, microvascular proliferation and, 101 
importantly, diffuse and widespread infiltration of single glioblastoma cells into the surrounding 102 
parenchyma [2].  103 
Glioblastomas are classified into three subtypes according to their morphology and 104 
molecular signature: classical, pro-neural, and mesenchymal. The classical subtype, the most 105 
proliferative of the three, is characterized by amplification of the epidermal growth factor 106 
receptor (EGFR), expression of EGFR variant III (EGFRvIII), molecular alterations affecting 107 
Notch, Sonic hedgehog (SHH) and Retinoblastoma (RB) pathways, and finally, loss of 108 
chromosome 10q, which contains the gene encoding for the phosphatase and tensin homolog 109 
(PTEN) protein [9]. The pro-neural subtype, accounting for nearly all secondary glioblastomas, 110 
displays molecular alterations in the platelet-derived growth factor A (PDGFRA), the isocitrate 111 
dehydrogenase 1 and 2 (IDH1/2), and the tumour protein 53 (TP53) genes; and is generally 112 
associated with better survival. Finally, the mesenchymal subtype, the most invasive of all 113 
phenotypes, is characterized by mutations in the neurofibromatosis type 1 (NF1) and PTEN 114 
genes, and by alterations affecting the NF-κB pathway. A fourth molecular signature called 115 
‘neural’ used to be considered as a relevant subtype for glioblastoma but has been eventually 116 
abandoned. This subtype displayed normal astrocyte phenotype, and low molecular alteration 117 
rates, but it was demonstrated to be the outcome of non-malignant cell contamination [10]. 118 
Overall, glioblastoma cells carry multiple and different mutations at recurrence, resulting from 119 
clonal and sub-clonal evolution [11]. 120 
Current standard treatments for glioblastoma consist of combination of chemotherapy 121 
with one of the most conventional alkylating agents, the Temozolomide, and radiotherapy, 122 
following surgical resection of the tumour [12]. However, the diffuse infiltration of glioblastoma 123 
cells into the surrounding tissue makes the complete surgical removal an impossible task, thus 124 
the surgical resection is never curative, and combined Temozolomide and radiotherapy 125 
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treatments only allow for the mild prolongation of the disease-free survival [13]. So far, several 126 
promising biomarkers for both diagnosis and prognosis have been identified in glioblastoma 127 
including the expression levels of MMP-9; presence of EGFRvIII; mutations in IDH1/2 and 128 
PTEN genes; methylation status of O-6-Methylguanine-DNA Methyltransferase (MGMT) gene 129 
promoter; loss of heterogeneity of chromosome 10q and 19q; and the levels of some miRNAs 130 
like miR-128 [14]. Identification of more specific biomarkers in the future, especially in liquid 131 
and solid biopsies would allow for better diagnostic and prognostic management of 132 
glioblastoma patients. 133 
 134 
The invasive nature of the glioblastoma tumour microenvironment 135 
In the brain, the normal ECM is enriched in hyaluronic acid, tenascin and lecticans, whereas 136 
fibronectin and fibrillar collagen are relatively low, which together confer a characteristic soft 137 
brain consistency [15]. The blood-brain barrier is formed by endothelial cells surrounded by 138 
the basement membrane and embedded pericytes. This capillary network is surrounded by 139 
astrocytes that provide the cellular link to neuronal cells [16]. During glioma progression, high 140 
dysregulation of the ECM composition is observed with glioblastoma cells expressing their own 141 
pro-invasive matrix, for instance, increased levels of tenascin and vitronectin [15, 17]. 142 
Contrarily, there is an apparent reduction of fibronectin expression in glioblastoma, which 143 
further promotes cancer cell invasion [18]. Moreover, there is an increase in the synthesis and 144 
degradation of hyaluronic acid, which allows for accumulation of low molecular weight 145 
hyaluronic acid thus facilitating invasion [19]. In addition, collagen is upregulated during glioma 146 
development and progression, despite being rare in the normal brain microenvironment [20]. 147 
In brain tumours, collagen acts as a scaffold that provides adhesion sites for cancer cell 148 
migration, as well as a reservoir for ECM components and growth factors that serve as ligands 149 
for diverse signalling pathways. In particular, glioma cells produce their own collagen, 150 
particularly type IV collagen, instead of type I collagen, which contributes to high tumour cell 151 
invasiveness [21]. In aggregate, such ECM alterations and increased density during 152 
progression of glioblastoma cells can dramatically increase their invasive properties [22]. The 153 
aforementioned ECM modifications that follow the invasive nature of glioblastoma clearly 154 
indicate the underlying involvement of distinct proteolytic networks, which create a unique ECM 155 
landscape to facilitate acquisition of critical hallmarks in glioblastoma progression. 156 
The progression of anaplastic glioma towards glioblastoma is sparked by vascular 157 
occlusion, which occurs within the tumour and induces severe hypoxia and necrosis [23]. 158 
Tumour cells migrate away from the hypoxic regions, creating a moving cellular wave from the 159 
central necrotic area towards the tumour edge (infiltrating edge). These cells, referred to as 160 
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pseudopalisading cells, have been encountered and exclusively described in glioblastoma 161 
tumours. They overexpress and secrete pro-angiogenic factors, such as VEGF, hypoxia-162 
inducible factor 1 (HIF-1) and interleukin 8 (IL-8) [1], which contribute to microvascular 163 
proliferation (endothelial hyperplasia), characteristic of grade IV gliomas. These cells migrate 164 
in the white matter zone of the brain, via myelinated axon tracts and the perivascular space.  165 
In the infiltrating edge, both pseudopalisading cells and tumour-associated macrophages 166 
(TAMs) co-exist, with the latter secreting pro-invasive cytokines and growth factors. The newly 167 
formed vasculature is leaky and poorly developed with abnormal basement membrane 168 
composition. During migration in the perivascular space, tumour cells are able to detach the 169 
astrocyte end-feet from blood vessels, contributing to the subsequent detachment of pericytes, 170 
and as such, the overall disruption of the blood-brain barrier [24]. Distinct proteolytic networks 171 
in the TME seem to play pivotal roles in forming and regulating this unique invasive pattern in 172 
glioblastomas, as will be later described in more detail in this review article. 173 
Indeed, a plethora of peptidases have been shown to play a critical role in glioblastoma 174 
progression and tumour invasion, especially in the context of forming proteolytic networks, or 175 
cascades. Glioblastoma and stromal cells interact within the TME via the expression and 176 
activity of a variety of proteolytic enzymes, such as metzincins peptidases (MMPs, ADAMs, 177 
ADAMTS), KLKs and cathepsins. These enzymes act from the first stage of cell invasion 178 
observed in progression from anaplastic glioma toward glioblastoma. During this process, cells 179 
anchor to the ECM via a panel of surface ligands including integrin receptors and the ECM is 180 
degraded by the proteolytic networks, thus assisting in cell migration [25]. However, 181 
glioblastoma cell invasion is not exclusively dependent on proteolytic degradation, because 182 
cancer cells adopt an alternative mode of migration, in which adhesion forces are low, and the 183 
cells migrate via squeezing movement mediated by actin contractility [25]. This alternative 184 
mode of cancer cell migration may harbour translational and clinical significance in 185 
glioblastoma treatment, and it could represent a major limitation to the therapeutic targeting of 186 
proteases in glioblastoma, as will be elaborated throughout this review article. 187 
 188 
Metzincin proteolytic enzymes in glioblastoma 189 
Family of Metzincin endopeptidases 190 
The Metzincin family belongs to the metalloproteinase family of endopeptidases, which is one 191 
of the five families of zinc endopeptidases (the others being: serine, threonine, aspartic, and 192 
cysteine), and named after the conserved Met residue at the active site, as well as the use of 193 
a zinc ion for their enzymatic activity. Matrix metalloproteinases (MMPs) and Adamalysins 194 
(ADAMs and ADAMTS) are protein subfamilies belonging to the broad Metzincin family. The 195 
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26 human MMPs can be categorized by their structural features and preferential substrates. 196 
They share three common domains: the pro-domain, the catalytic domain, and the hemopexin-197 
like C-terminal (Hpx) domain linked to the catalytic site (Fig. 1A). MMPs can either be localized 198 
in the cell surface or be secreted. The pro-MMP (or zymogen) inactive protein can become 199 
active after the proteolytic removal of the pro-domain in the intracellular and extracellular space 200 
[26]. Secreted MMPs can be further classified according to their preferential ECM substrates. 201 
For instance, interstitial collagenases (MMP-1, -8 and -13) mainly target fibrillar collagens (type 202 
I, II and III), while gelatinases (MMP-2 and -9), also called type IV collagenases, mainly target 203 
basement membrane collagens, gelatine, and elastin. Stromelysins (MMP-3, -10 and -11) are 204 
unable to degrade collagens, but instead target several ECM proteins, such as proteoglycans, 205 
fibronectins, and laminins. Finally, matrilysins (MMP-7 and -26) target similar substrates as 206 
stromelysins, but do not contain the Hpx domain [27] (Fig.1A). MMPs are also able to cleave 207 
inactivated forms of other MMPs (pro-MMPs), as well as pro-forms of growth factors, resulting 208 
in their subsequent activation. MMPs that are localized to the cell surface (MMP-14, -15, -16, 209 
17, 24, -25) are activated during their trafficking to the cell membrane [27]. In the extracellular 210 
space, MMPs are susceptible to inhibition by tissue inhibitors of metalloproteinases (TIMPs). 211 
TIMPs can bind to the active site of proteases to form a complex that will be recognized and 212 
engulfed by macrophages [28]. MMPs are further activated when secreted without their 213 
respective inhibitors, therefore, cell compartmentalization is critical for the tight regulation of 214 
their activity. MMPs function in a variety of physiological processes that require a specific ECM 215 
(re)arrangement, as well as in multiple pathological processes, such as inflammation, 216 
autoimmunity, and cancer. In the brain, they significantly contribute to tissue formation, 217 
neuronal network remodelling and blood-brain barrier integrity. Importantly, MMPs are involved 218 
in most brain diseases with a neuro-inflammatory component (i.e. Alzheimer’s and Parkinson’s 219 
diseases) and in CNS cancers [16]. MMPs implicated in cancer progression are mainly 220 
expressed in the tumour cells, but also in the tumour-associated stromal cells. 221 
The subfamily of Adamalysins contains the Disintegrin and metalloproteinases 222 
(ADAMs) membrane-bound proteins, which primarily exert functions in the pericellular space. 223 
ADAM family members contain several conserved domains: the pro-domain; the MMP domain 224 
responsible for a sheddase activity (which is not functional in every ADAMs); a disintegrin 225 
domain  for integrin binding and cell adhesion; a cysteine-rich domain for cell adhesion via 226 
interaction with syndecan; a cytoplasmic domain which serves as phosphorylation site domain; 227 
and an EGF-like domain with unknown function [29] (Fig.1A). ADAMs support cell proliferation 228 
and apoptosis via growth factor shedding, but also participate in cell adhesion, migration, and 229 
signalling [30]. Another subfamily of Adamalysins, represented by the ADAM via 230 
thrombospondin motif (ADAMTS) proteins, are generally secreted and soluble proteins 231 
containing a thrombospondin domain that allows them to interact with adhesion molecules 232 
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such as integrin receptors. Unlike ADAMs, ADAMTSs, do not contain the EGF-like, 233 
transmembrane, and cytoplasmic domains (Fig.1A). They also exhibit proteolytic activity, 234 
similar to other members of the family, and, as such, they mainly target ECM proteins [31]. 235 
Role of metzincin endopeptidases in glioblastoma progression 236 
Both ECM remodelling and degradation mediated by MMP-induced proteolytic cleavage play 237 
a major role in cancer cell invasion. MMP-14 disrupts fibrillar collagen, therefore inducing its 238 
rearrangement in the pericellular space and contributing to cancer cell invasion [25]. ADAMs 239 
have similar and complementary mechanisms of action in cancer progression with MMPs. 240 
Notably, they suppress apoptosis induction via the shedding of Fas ligand from the cell surface 241 
[32], cleave E-cadherin [33], and activate EGFR ligands [34]. In general, there is evidence 242 
demonstrating that both MMPs and ADAMs together contribute to cancer progression and are 243 
part of podosome-related proteases. In actin-rich podosomes of migrating cells, the scaffold 244 
protein Tks5/FISH binds to ADAMs where MMP-2, -9 and -14 are present and promote 245 
invasion via direct ECM degradation [35].  246 
In glioma, the expression of multiple MMPs (MMP-1, -2, -7, -9, -11, -12, -14, -15 and -247 
19) has been shown to be positively correlated with glioma grades [36], while 11 MMPs (MMP-248 
1, -2, -7, -8, -9, -10, -11, -14, -15, -19 and -23)  have been shown to be significantly 249 
overexpressed in glioblastoma [37] (Table 1). Apart from MMP-15 and -19, the overexpression 250 
of these MMPs is correlated with poor survival. It is worth noting that the expression of furin, 251 
an enzyme that activates MMPs, is strongly associated with poor overall survival in 252 
glioblastoma [2], with the furin inhibition in astrocytoma cells leading to reduction in cell 253 
migration [38]. In general, more than half of human MMPs are correlated with glioblastoma 254 
progression, with MMP-2 and -9, being the most significant ones.  255 
MMP-9 in glioblastoma progression 256 
MMP-9, among all MMPs, has been considerably involved in glioblastoma progression. MMP-257 
9 is considered a significant prognostic factor, since its overexpression correlates with 258 
increased invasive glioma grades [39]. Low MMP-9 expression is associated with favourable 259 
outcome and response to Temozolomide treatment [40]. Overexpression of MMP-9 triggers 260 
proliferation in glioblastoma cell lines, while its blockade decreases the volume, weight, 261 
microvessel density, and proliferation activity in mouse tumours [41]. Several mechanisms of 262 
regulation have been suggested for MMP-9 activation in glioblastoma, including the uPA/uPAR 263 
system. Urokinase plasminogen activator (uPA), a serine protease, is upregulated in high-264 
grade gliomas [42], and converts plasminogen into plasmin, with better efficacy when anchored 265 
to its receptor uPAR. Plasmin, in turn, is responsible for both MMP and uPA activation [2]. uPA 266 
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is also capable of directly activating MMP-9 via proteolytic cleavage, which in turn, degrades 267 
fibronectin and therefore leads to glioblastoma progression [43] (Fig.2A). 268 
MMP-9 is also a component of several intracellular signalling pathways. In 269 
glioblastoma, MMP-9 expression is positively correlated with EGF and EGFR expression. 270 
MMP-9 and EGFR are both present in the cerebrospinal-fluid (CSF) of patients and their levels 271 
decline after tumour resection. MMP-9 transcription is stimulated by EGFR and EGFRvIII in 272 
glioblastoma, with signalling pathways involved such as PI3K/AKT (PKB), STAT3/5, NFk-B, 273 
ERK and Sonic hedgehog (SHH) [44-46]. MMP-9 can cleave several ECM components, 274 
preferentially type IV collagen, gelatine, and elastin; but also, regulates cell-ECM interactions: 275 
MMP-9 is able to act on cell motility via direct cleavage of CD44, a surface glycoprotein 276 
involved in cell-ECM interactions via binding to several ECM ligands, mainly hyaluronic acid. 277 
Shedding of CD44 by MMP-9 releases its extracellular portion and contributes to cell migration 278 
and invasion [47] (Fig.2B). In an in vitro model of glioblastoma carrying PTEN mutation, 279 
deficiency of the PTEN phosphatase activity leads to hyaluronic acid-induced phosphorylation 280 
of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK) 1/2. These 281 
signals further lead to increased invasion via MMP-9 expression [48].  282 
Finally, MMP-9 has been shown to function as a mediator of neo-angiogenesis. In 283 
glioblastoma, MMP-9 is expressed in proliferative endothelial cells [49] where it can degrade 284 
basement membrane, clearing up the space for endothelial cell migration and therefore 285 
supporting neo-vasculature formation (Fig.2C). This is further supported by the fact that MMP-286 
9 expression is correlated with VEGF expression in glioblastoma, which is the most crucial 287 
regulator of angiogenesis. Proliferation and migration of endothelial cells via VEGF in 288 
glioblastoma is dependent on the binding of VEGF to VEGFR-2, which is upregulated [50]. 289 
MMP-9 expression, induced by the hypoxia factor HIF-1, leads to increased VEGF action by 290 
acting on its bioavailability within the extracellular space [51] (Fig.2C). MMP-9 is also 291 
expressed by cells resembling vascular smooth muscle cells and pericytes, and contributes to 292 
their proliferation in glioblastoma [52].  293 
MMP-2 and -14 in glioblastoma progression 294 
Similar to MMP-9, MMP-2 also plays a prominent role in glioblastoma progression, mainly 295 
through ECM and cell-adhesion proteolytic degradation (Fig.2B). MMP-2 is localized in the 296 
tumour neo-vasculature in glioblastoma [49], and is mainly expressed in endothelial cells and 297 
pseudopalisading cells surrounding the peri-necrotic areas. High MMP-2 expression is 298 
associated with advanced tumour grade and poor survival. Interestingly, the hepatocyte growth 299 
factor (HGF), which is co-expressed with MMP-2 and c-MET (the receptor of HGF) is also 300 
associated with shorter survival in glioblastoma [53]. MMP-2 and HGF are both activated by 301 
plasmin in the extracellular space (Fig.2A) and c-MET in glioblastoma is associated with 302 
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endothelial cell proliferation, migration, and aberrant vascularization [54]. Similar to MMP-9, 303 
MMP-2 is also induced by hypoxia, but is mostly expressed within the pseudopalisading area 304 
compared to endothelial cells [55]. Angiopoietin-2 (Ang-2), a protein which is upregulated in 305 
the infiltrative area of glioblastoma, interacts with avb1 integrin. This interaction triggers several 306 
intracellular signalling relays, which include: FAK, ERK1/2 and c-jun N-terminal kinase (JNK) 307 
and leads to MMP-2 expression, hence collectively contributing to increased angiogenesis and 308 
invasion [56] (Fig.2C).  309 
MMP-2 is responsible for activation of growth factors via two major mechanisms. It can 310 
directly cleave and activate the latent forms of TGFb1 and TGFb2, but can also release, via 311 
proteolytic cleavage, VEGF, bFGF and TGFa that are sequestered to the ECM, making them 312 
bioavailable within the extracellular space [57].  MMP-2 proteolytically degrades collagen with 313 
the help of integrin binding and its expression is also mediated via collagen binding to collagen 314 
receptors. Activation of MMP-2 and subsequent invasion in glioblastoma is upregulated after 315 
binding of Discoidin domain receptor 1 (DDR1)a, overexpressed in glioblastoma, to collagen 316 
[58] (Fig.2B). MMP-2 also mediates pro-oncogenic intracellular signalling via indirect 317 
interaction with integrins. In glioblastoma, MMP-2 is activated on the cell surface by a protein 318 
complex that includes the vitronectin-binding integrin avb3, which is mostly prevalent in the 319 
invasive edge and newly formed blood vessels in glioblastoma [59].  Furthermore, MMP-2 can 320 
form a multi-protein complex with integrin avb1, which upregulates IL-6 expression, activation 321 
of STAT3 and expression of c-Myc and cyclin D1, leading to cancer cell survival signalling [60].  322 
MMP-14 (MT1-MMP) is another endopeptidase whose expression is associated with 323 
increased VEGF expression in glioblastoma [50]. Co-expression of MMP-14 and MMP-19 is a 324 
predictive survival factor in glioblastoma patients [61]. MMP-14 is predominantly expressed by 325 
TAMs in glioblastoma and acts mainly by activating MMP-2 after cleavage of its pro-domain. 326 
MMP-14 expression in TAMs is induced through activation of Toll-like receptors (TLRs) and 327 
ensuing activation of the p38 MAPK pathway in glioblastoma cells [62] (Fig.2A). Importantly, 328 
in glioblastoma, endothelial cells undergo an endothelial-to-mesenchymal transition (EMT) 329 
during which the cells acquire a ‘fibroblast-like’ phenotype while maintaining their original 330 
endothelial functions. In those cells, MMP-14, whose expression is mediated by c-MET 331 
activation, mediates direct cleavage of vascular endothelial (VE)-cadherin [54], contributing to 332 
increased vascular permeability. 333 
Other Metzincins in glioblastoma progression 334 
Other members of the MMP family, have also been found to be implicated in glioblastoma 335 
progression and invasion to a lesser extent. These include: MMP-1 via the MAPK pathway 336 
[63], MMP-3 via the NF-kB pathway [64], MMP-7 and ADAM-9 via the ERK pathway [65, 66] 337 
and MMP-12 and ADAM-9 via tenascin-C [67, 68]. MMP-1 is upregulated in glioblastoma along 338 
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with the protease-activated receptor 1 (PAR1) and their co-expression is predictive of poor 339 
prognosis. MMP-1 acts by cleaving PAR1, thus inducing its activation and contributing to 340 
glioblastoma progression [69]. Expression of MMP-1, -11 and -19 have been positively 341 
correlated with glioma grades and potentially constitute diagnostic markers in glioblastoma 342 
[70]. MMP-11 expression in glioblastoma is localized in endothelial cells, whereas MMP-1 and 343 
MMP-19 are expressed in the cytoplasm of glioblastoma cells, with MMP-19 strongly 344 
expressed in the invasive edge. Likewise, MMP-26 expression positively correlates with glioma 345 
grades in patients and its overexpression in vitro results in increased invasion ability and 346 
microvessel density [71, 72]. Finally, invasion in glioblastoma is also mediated by MMP-13, 347 
whose expression is at least in part the result of the integrin-liked kinase (ILK)-mediated 348 
activation of the ROCK1/fascin-1 pathway [73]. Its downregulation promotes inhibition of 349 
glioblastoma stem cells invasion capacity in vitro [74]. Interestingly, the implication of 350 
endopeptidases, both ADAMs and MMPs, has been correlated with EGFR activation in 351 
multiple contexts in glioma: e.g. ADAM-17 during the transition to mesenchymal subtype [75, 352 
76] and MMP-1 in invasion of glioma cell lines [63].  353 
Similar to MMPs, ADAMs and ADAMTSs also play prominent roles in glioblastoma 354 
progression. ADAMTS-5 is overexpressed in glioblastoma cell lines in vitro and in glioblastoma 355 
patients, and may contribute to invasion as it is able to degrade brevican, a member of the 356 
lectican family overexpressed in glioblastoma ECM [77]. ADAM-9 has been positively 357 
correlated with advanced glioma grades [78]. In addition, hypoxia induces ADAM-17 358 
expression in glioblastoma and contributes to the invasion and malignant phenotype via the 359 
EGFR/PI3K/AKT pathway activation [79]. ADAM-17 inhibition hampers tumour growth in mice 360 
whereas its overexpression induces TGF-α and VEGF secretion [79]. Finally, ADAMs, which 361 
are membrane-bound, exert a sheddase activity on the surrounding membrane-bound pro-362 
growth factors, resulting in the release of their activated form in the extracellular milieu 363 
(Fig.2A).  For instance, ADAM-12 is overexpressed by glioblastoma cells and associated with 364 
increased proliferation activity via the shedding of heparin-binding factor EGF (HB-EGF) [30].  365 
Overall, MMP-9, but also MMP-1, -2, -7, 11, and -14, represent very attractive 366 
biomarkers and therapeutic targets for glioblastoma: first, they can serve to anticipate the 367 
survival and identify the grade; secondly, they are significantly overexpressed and involved in 368 
the disease progression. Of note, these biomarkers have been essentially assessed in solid 369 
biopsies from patients, except for MMP-9, whose level was also detected in the CSF [44]. On 370 
the other hand, some other MMPs seem to be promising but do not necessarily fit all four 371 
above-mentioned characteristics. Some ADAM/ADAMTSs seem to represent interesting 372 
targets, but for most of them, their potential as biomarkers needs further elucidation, although 373 
ADAM-9 and -17 should be useful at least as solid biopsy diagnostic biomarkers (Table1).  374 
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Kallikrein protein family in glioblastoma 375 
Kallikreins (KLKs) and the kallikrein-kinin system 376 
The kallikrein-kinin system is involved in vascular permeability, inflammatory response, 377 
thrombosis and blood coagulation [80]. The kallikrein family is a family of secreted serine 378 
proteases [81] encompassing the human tissue kallikrein-related peptidases (KLKs). KLKs are 379 
expressed by a variety of tissues; one of the most well established is the prostate-specific 380 
antigen (PSA), also termed KLK3, which has broadly been used as a biomarker for prostate 381 
cancer [82]. KLKs share a common structural motif: they contain a signal peptide and a pro-382 
domain and are activated after proteolytic cleavage. KLKs have a single active site comprised 383 
of a triad of serine, aspartic and histidine residues as also found in the active site of trypsin 384 
[83] (Fig.1B). It is known that KLKs convert kininogens to kinins. KLKs are implicated in a 385 
variety of  pathophysiological processes, including cancer [84]. Physiologically, KLKs are 386 
involved in inflammatory response, skin desquamation, enamel formation, and semen 387 
liquefaction. Of note, they act on PAR receptors and can modulate signalling pathways, 388 
degradation of the ECM, cleavage of junction proteins, and EMT, thereby playing a critical role 389 
in cancer invasion and migration [85]. 390 
 391 
KLKs in glioblastoma progression 392 
Growing evidence suggests that KLK deregulation and overexpression in a variety of 393 
malignancies have uncovered their potential as cancer biomarkers [82]. KLKs are significant 394 
mediators of cancer progression, for instance via releasing growth factors from the ECM 395 
network [86], including the IGF active form [87]. In addition, KLK4 and 5 mediate activation of 396 
HGF via direct cleavage and activation of its potent activator, pro-HGF activator (pro-HGFA) 397 
[88]. Accumulating evidence also suggests the involvement of KLKs in the central nervous 398 
system (CNS) normal physiology and pathological processes [89]. KLKs are notably implicated 399 
in CNS-mediated diseases such as Alzheimer’s disease and multiple sclerosis (KLK6) [85]; 400 
bipolar disease (KLK8) and intracranial tumours (KLK6 and 8) [90, 91]. To date, KLK6, KLK7 401 
and KLK9, which are preferentially expressed in the CNS [92], have demonstrated prognostic 402 
value in glioblastoma.  403 
KLK6 is highly expressed in the brain and its expression is upregulated in glioblastoma 404 
compared to lower-grade brain tumours, such as meningiomas. KLK6 expression is correlated 405 
with higher tumour grades and histologic types in intracranial tumours, with poor post-surgical 406 
survival in glioblastoma patients [90]. In the brain, KLK6 plays major roles in normal CNS 407 
functions in different cell types, mainly through its interaction with PAR1 (which can also be 408 
activated by thrombin). KLK6 activates the ERK1/2 pathway through activation of PAR1 to 409 
modulate the myelination process in normal oligodendrocytes [93]. In astrocytes, KLK6 can 410 
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modulate inflammation and plasticity through activation of PAR1, which results in cellular 411 
stellation, nuclear translocation of b catenin, cellular aggregation, and IL-6 secretion [94]. In 412 
glioblastoma, KLK6 also cleaves and activates PAR1 and PAR1 is significantly upregulated in 413 
patients (Fig.2A). This interaction induces resistance to apoptosis and to cytotoxic agents via 414 
increased level of Bcl and inhibition of Bim [95]. Recently a specific inhibitor, which prevents 415 
activation of PAR1 at thrombin (and thrombin-like protease) cleavage site, resulted in 416 
decreased proliferation and improved survival in vivo in glioblastoma [96]. This inhibitor was 417 
not designed to block KLK6-mediated activation of PAR1; however, this study highly supports 418 
that the KLK6/PAR1 pathway could be a potential target in glioma.  419 
 Likewise KLK6, KLK7 and KLK9 expressions have been shown to be associated with 420 
poor patient prognosis and poor survival in glioblastoma [97]. Another study has suggested 421 
that KLK7 overexpression in glioblastoma cell lines significantly enhanced invasiveness in an 422 
in vitro Matrigel assay [91]. It is also worth noting that KLK genes are arranged tandemly on 423 
chromosome 19q (19q13.33) and that gain of 19q chromosome is a poor prognostic factor in 424 
glioblastoma while loss of chromosome 19q is associated with better survival [98].  425 
Overall, KLK6 seems to be an ideal biopsy biomarker for glioblastoma patients as it 426 
can anticipate both grade and survival. For KLK7 and KLK9, there is a lack of evidence in 427 
respect of their potential use in diagnosis. Finally, studies investigating the effect of kallikrein 428 
inhibition in glioblastoma still remains to be elucidated before this type of therapeutic approach 429 
may be considered in clinics (Table 1).  430 
 431 
Cathepsin peptidases in glioblastoma 432 
Cathepsin peptidases 433 
Cathepsins belong to an extensive family of peptidases, which are mostly active in endosomes 434 
and lysosomes in normal conditions and are involved in antigen presentation and processing, 435 
activation of proteins, lysosomal death pathway, autophagy, and aging. They are distributed in 436 
different families of proteases: cysteine, serine, and aspartyl proteases. Cathepsins have a 437 
heterogeneous panel of substrates, mainly within the extracellular space, which includes the 438 
Bcl2 homolog, various chemokines, transmembrane receptors, adhesion proteins and ECM 439 
components [99]. Most cathepsins have a main endopeptidase activity. However, some have 440 
both an endo- and an exopeptidase activity, which is the case for cathepsin B, while others are 441 
exclusively exopeptidases (e.g. cathepsins X/Z and C) [100]. Cysteine cathepsins belong to 442 
the papain family of cathepsin proteases. They are synthetized as inactive pro-enzymes 443 
(Fig.1B). Upon cleavage of the N-terminal signal peptide in the endoplasmic reticulum and 444 
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glycosylation in the Golgi apparatus, the pro-peptide is targeted to the lysosome. Proteolytic 445 
cleavage of the pro-enzyme is then required for activation and is initiated by acidic pH in 446 
lysosomes. In the extracellular compartment, cysteine cathepsins only remain weakly active at 447 
neutral pH, except for cathepsin S [101]. Cathepsins play a role in many diseases such as 448 
cancer, as well as neurodegenerative, inflammatory, and cardiovascular disorders [99]. 449 
Cysteine cathepsins comprise CatB, L, K, S, and X. They contain three conserved residues 450 
(cysteine, histidine, and asparagine) within their single active site (Fig.1B). CatB and L are 451 
expressed in several tissues including the brain, whereas CatK and S display more restricted 452 
expression. For instance, CatL is expressed in astrocytes, neurons, and microglial cells, while 453 
CatK is mainly expressed by hematopoietic and epithelial cells. CatB can be activated by 454 
autocatalytic cleavage of the pro-domain, or by CatD, or by other proteases such as uPAR and 455 
elastases [102]. In addition to normal protein secretion, CatB secretion occurs via shedding of 456 
membrane vesicles and exosomes [103]. CatD is a bilobed protein belonging to the family of 457 
aspartyl proteases, with two critical aspartic residues, one on each lobe, belonging to its active 458 
sites (Fig.1B). In the brain, in addition to ECM degradation, CatD is responsible for specific 459 
cleavage and processing of myelin and other brain-associated proteins, conversion of pro-460 
collagen into collagen and activation of the inhibitors of cysteine proteases [104]. Cathepsins 461 
and MMPs have been shown to be part of a common proteolytic network. Indeed, CatB has 462 
been found to proteolytically activate uPA and MMPs, but also to inhibit TIMP-1 [105-107]. In 463 
addition, CatK has been shown to activate MMP-9 through proteolytic cleavage [108], 464 
subsequently promoting cancer progression and metastasis. 465 
 466 
CatB and K in glioblastoma progression 467 
Both CatB expression and enzymatic activity are correlated with high tumour invasion and 468 
grading in glioblastoma. CatB in glioblastoma is relocated from the lysosomal compartment to 469 
the cell membrane and is expressed in invasive tumour areas [109, 110]. Moreover, it has 470 
been demonstrated that CatB contributes to glioblastoma invasiveness and angiogenesis both 471 
in vivo and in vitro via MMP-9 and VEGF upregulation, hence this protease represents a 472 
potential therapeutic target [111]. Other studies have shown that simultaneous downregulation 473 
of CatB, MMP-9 and uPAR decreases cancer cell-ECM adhesion via reducing the active 474 
integrins, consequently inhibiting cell migration [112]. Another study demonstrated that CatB 475 
and uPAR upregulation results in activation of cycline/CDK via phosphorylation of ERK, 476 
ensuing the parallel induction of c-Myc and the downregulation of p27 (an inhibitor of CDK) 477 
[113]. In addition, the concomitant expression of CatB and uPAR induces angiogenesis by 478 
upregulation of VEGF expression through the JAK/STAT signalling pathway [114].  479 
CatB is active and highly expressed throughout the entire tumour by glioblastoma cells 480 
and glial cells. On the contrary, CatK is less active, and expressed by glioblastoma cells and 481 
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glioma stem cells (GSCs) that are restricted to the peri-vascular area [115]. Among the GSCs, 482 
CXCR4-expressing cells are attracted by the chemoattractant stromal-derived factor-1a (SDF-483 
1a), which is contained in the perivascular niche and secreted by endothelial and stromal cells. 484 
CatK is responsible for the cleavage and inactivation of SDF-1a. Such inactivation promotes 485 
the release of GSCs out of the niche, which further induces loss of stemness and increased 486 
sensitivity to radiation and chemotherapy. Therefore, upregulation of CatK could serve as a 487 
strategy to enhance therapeutic efficacy in glioblastoma. Other cathepsins might be able to 488 
inactivate SDF-1a, like CatB for example, which is highly present in tumour endothelial cells in 489 
GBM [116, 117]. Moreover, CatK might be involved in the tumorigenic mechanisms similar to 490 
other cysteine cathepsins. For the above-mentioned reasons, it might be more tempting to 491 
target SDF-1a directly, instead of CatK.  492 
 493 
Other cathepsins in glioblastoma progression 494 
Cathepsin D (CatD), an aspartyl protease, is a potential biomarker for glioblastoma, and its 495 
expression positively correlates with high histological grade, poor prognosis and 496 
leptomeningeal dissemination [104]. CatD is a major component of lysosomes and a high 497 
number of lysosomes are found at the plasma membrane of GBM cells, when compared with 498 
normal astrocytes. Inhibition of lysosome exocytosis prevents glioblastoma cell invasion in a 499 
3D model and reduce the number of lysosomes on the cell surface, mediated by inhibition of 500 
CatD exocytosis [118] (Fig.2C). CatS, which is a cysteine cathepsin, is not expressed in normal 501 
glial cells, neurons, or endothelial cells, but is expressed in glioblastoma cells. Moreover, CatS 502 
expression is higher in glioblastoma compared to lower-grade glioma cells and inhibition of 503 
CatS in vitro reduces the invasion of glioblastoma cells [119]. CatS has also been suggested 504 
as a prognostic factor in glioblastoma [120]. Contrarily, other studies argue against the 505 
involvement of CatS in glioblastoma invasion [121], suggesting that its role in glioblastoma 506 
progression needs to be further elucidated. In GBM tissue samples, CatZ (or X), another 507 
cysteine cathepsin, can be found highly expressed in peri-arteriolar GSC niches but also in 508 
GBM cells and endothelial cells throughout the entire tumour. CatZ/X expression is also 509 
associated with poor prognosis and thus constitutes a potential prognosis factor [115, 122]. 510 
 Serine cathepsins (A and G) have not been shown to be overexpressed or be 511 
responsible for invasion in glioblastoma. However, the absence of CatG in glioblastoma cells 512 
could support tumour progression as was recently discussed. CatG is not expressed in 513 
glioblastoma cells and low expression is found in endothelial cells within the tumour 514 
microvasculture [123]. GSCs do not contain CatG, which normally cleaves MHC class I in 515 
immune cells. Cleavage of MHC class I molecule renders the cells recognizable to natural killer 516 
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cells. Increasing the levels of CatG in glioblastoma cells, using lactoferrin, could thus be an 517 
interesting therapeutic strategy in glioblastoma as this would enhance immune recognition and 518 
elimination of tumour cells [124].  519 
In aggregate, CatB, L, D, S and Z/X are upregulated in glioblastoma. CatB, D, S, and 520 
Z/X display promising features, both as biopsy biomarkers and therapeutic targets (Table 1). 521 
Finally, there is some supporting evidence that CatL could be used as a biomarker to anticipate 522 
response to radiotherapy.   523 
 524 
  Strategies for therapeutic targeting of proteolytic enzymes in glioblastoma  525 
   MMP-targeted therapies in glioblastoma 526 
Small molecule MMP inhibitors (MPIs) have been previously developed for contextually 527 
impeding proteolysis-driven cancer progression. The mechanisms of their action are divided 528 
into different categories. The peptidomimetic inhibitors (i.e. Batimastat and Marimastat) mimic 529 
the structure of collagen at the MMP cleavage site and, as such, act as competitive inhibitors. 530 
On the other hand, non-peptidomimetic inhibitors (i.e. Tanomastat and Prinomastat) mimic the 531 
3D conformation of the MMP active site [26]. In addition, chemically modified tetracyclines 532 
have been used to inhibit MMP activity via zinc binding. Other specific molecules that have 533 
been developed to inhibit specific MMPs (MMP-2 and -9) have also been suggested for 534 
therapies, such as CGS-27023A and SB-3CT [26].  535 
Two drugs that function as MMPs inhibitors, Marimastat and Prinomastat have both 536 
revealed promise in treating glioblastoma. Marimastat is a broad spectrum metzincin inhibitor, 537 
which ultimately was shown to have limited impact on progression-free and overall survival. In 538 
a recent study, the use of Marimastat in combination with Temozolomide and radiation resulted 539 
in downregulation of MMP-14 via the parallel downregulation of microRNA374 and induction 540 
of cell cycle arrest. Of note, Marimastat specifically inhibits the growth of cancer cells but not 541 
that of normal astrocytes [125]. However, in Phase II trial, the use of Marimastat with 542 
Temozolomide in anaplastic glioma not only showed very limited improvement of 543 
chemotherapy efficacy compared to standard treatment, but also generated additional joint 544 
toxicity [126]. Prinomastat, on the other hand, is a relatively specific MPI that targets MMP-2, 545 
-3, -9, -13 and -14, which all together highly contribute to angiogenesis and invasion observed 546 
in glioblastoma as mentioned above. Prinomastat-treated gliomas in mice are smaller in 547 
tumour size, have lower rates of proliferation and are less invasive compared to untreated 548 
gliomas [127].  This drug has been associated with high toxicity and lack of efficacy during 549 
phase III clinical trials [128], hence, its potential applicability is currently set aside. 550 
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Other molecules that are more selective MPIs have also been tested in glioma models. 551 
MMI-166, a third-generation MPI that selectively inhibits MMP-9, -2 and -14, reduces invasion 552 
and angiogenesis in vitro and hinders tumour growth in mice [129]. Moreover, synthetic MPIs 553 
that specifically target the gelatinases MMP-2 and -9 reduce glioblastoma cell invasion. For 554 
instance, inhibitors such as the N-O-isopropyl sulfonamido-based hydroxamate compounds 555 
(code CGS-27023A) were found to reduce MMP-2 at mRNA and protein levels. In combination 556 
with Temozolomide, they also reduce invasiveness and cell viability in vitro and importantly, 557 
they work at low concentrations, which would help to reduce toxicity [130]. Recent technologies 558 
for improved therapies have now been suggested for MMPs. Nanoparticles (NPs) are shown 559 
to affect MMP expression and activity in vivo and in vitro. Carbon-based NPs seem to have 560 
inhibitory effects on MMPs, but the factors by which these effects are modulated are not yet 561 
fully understood [131]. Alternatively, delivery of Marimastat to the TME by lysolipid-containing 562 
thermosensitive liposomes (LTSLs) has also been tested for their high vascular permeability 563 
[132]. These LTSLs deliver their content only after heat treatment at 42 oC. The treatment at 564 
the in vivo and in vitro level allowed MMP-2 and -9 inhibition as well as reduction of metastasis 565 
and angiogenesis in lung cancer models. These models may constitute a potential novel 566 
treatment for glioblastoma. 567 
Strategies to inhibit MMPs in glioblastoma are still under investigation. The most recent 568 
studies have revealed several novel inhibitors of MMPs while simultaneously highlighting a 569 
better understanding of their transcriptional regulation. The transcription factor NFE2L2 is 570 
upregulated in Temozolomide-resistant glioblastoma cells and responsible for MMP-2 571 
expression via direct binding to its promoter region. The use of Diosgenin to inhibit NFE2L2 572 
effectively reduced Temozolomide resistance in glioblastoma cells, via reduction of MMP-2 573 
expression level, increased apoptosis, and decreased migration [133]. Another study revealed 574 
that the ectopic expression of the transcription factor brain and muscle ARNT-like 1 (BMAL1) 575 
could be used to decrease AKT phosphorylation level and MMP-9 expression and thus, inhibit 576 
migration and proliferation of glioblastoma cells [134]. Sinomenine hydrochloride, a bioactive 577 
alkaloid, is able to decrease invasion of glioblastoma cells through activation of autophagy and 578 
suppression of NFkB activation with subsequent decrease in MMP-2/MMP-9 level [135]. At 579 
last, the actin-related protein 10 (ARP10) has been shown to inhibit MMP-14 auto-proteolytic 580 
processing, and consequently MMP-2 activation, in addition to trigger autophagy-mediated cell 581 
death [136]. These recent studies confirm that MMPs still represent promising targets in 582 
glioblastoma and that investigations elucidating their mediated mechanisms would still be 583 
beneficial for development of novel therapeutics.   584 
To sum up, small molecule MMP inhibitors (MPIs) have been previously developed, 585 
and some of them have been tested in glioblastoma patients. Nonetheless, MPIs so far have 586 
shown limited efficacy in clinical trials for improving the survival potential. This could be partly 587 
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explained by the tumour suppressive roles that MMPs have been shown to display during 588 
specific time-windows of tumour progression. For instance, MMP-9 is responsible for a rapid 589 
increase of angiogenesis at early stage of tumour progression during which it degrades 590 
basement membrane components. However, the resulting products of basement membrane 591 
cleavage by MMP-9 can have an anti-angiogenesis effect. This has been demonstrated for 592 
tumstatin, a cleavage product of MMP-9, which hampers tumour development during the later 593 
stage of progression [137]. In addition, several protective effects against cancer have been 594 
found for MMPs in different types of cancer. For example, MMP-12 in melanoma has a clear 595 
anti-angiogenesis effect via stimulation of angiostatin [138]. MMP-19 in nasopharyngeal 596 
carcinoma is downregulated and its transfection in nude mice suppresses tumour formation 597 
[139]. MMP-8 is a good prognosis factor in breast cancer and has been found responsible for 598 
promoting decreased invasion [140]. In prostate cancer, MMP-26, which has pro-apoptotic 599 
functions, is highly expressed at early stage and decreases during cancer progression [141]. 600 
Nevertheless, it is unclear if these MMPs also have tumour-suppressive effects in 601 
glioblastoma, but lessons should be learned from their application in other types of cancer, and 602 
careful considerations should be made for avoiding similar drawbacks in the glioblastoma 603 
therapeutics field. 604 
 605 
KLK inhibitors as a potential therapeutic strategy in glioblastoma 606 
KLK-targeted therapies have also been suggested in certain types of cancer, supporting their 607 
potential role as therapeutic targets for glioma. For instance, it has been suggested that PSA 608 
should be targeted in prostate cancer. PSA has been shown to be involved in prostate cancer 609 
progression by stimulating cell proliferation in vitro and cancer growth in vivo [142]. Several 610 
peptide-based or small molecule inhibitors for PSA have been developed and tested in vitro 611 
and in vivo [142]. Other KLKs represent interesting therapeutic targets in cancer as well. For 612 
instance, inhibition of KLK7, which is upregulated in pancreatic cancer, resulted in decreased 613 
proliferation and migration in vitro [143]. A high number of KLK inhibitors with different 614 
molecular mechanisms of action are already available [144].  615 
Regarding glioblastoma, there is an evident lack of preclinical studies related to the 616 
inhibition of kallikreins. Therefore, such studies need to be further conducted for suggesting 617 
KLKs as potential therapeutic targets in glioblastoma. As mentioned above, in glioblastoma, 618 
KLK6 promotes resistance to apoptosis [95]; KLK7 overexpression promotes increased 619 
invasion in vitro [91]; and both, along with KLK9, are associated with poor survival in patients 620 
[97]. These results make kallikreins attractive candidates for glioblastoma therapeutics, yet the 621 
effect of their inhibition in vitro and in vivo needs to be elucidated. Moreover, the potential 622 
protective role of KLKs during cancer progression must be considered, as in the case of MMPs. 623 
For instance, KLK8 is known to be a good prognosis marker in ovarian cancer. Importantly, 624 
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degradation of fibronectin induced by KLK8 is responsible for suppression of cell motility via 625 
suppression of integrin signalling [145]. Thus, the ability of proteases to degrade the ECM can 626 
confer protective role in cancer, even though these cases remain rare so far. Overall, KLK6 627 
and KLK7 are the most promising targets for glioblastoma treatment among all known KLKs.  628 
Cathepsin inhibitors as a potential therapeutic strategy in glioblastoma 629 
Inhibition of cathepsin peptidases in cancer has also been investigated. KGP94 is a small 630 
inhibitor of CatL and has been tested in vitro in breast and prostate cell lines [146]. This study 631 
showed that CatL has pro-migratory effects on these cells and this can be mediated both by 632 
increased lysosomal exocytosis and increased CatL intracellular level; importantly, this effect 633 
can be prevented by KGP94. Inhibition of cathepsins in glioblastoma could represent an 634 
effective targeted chemotherapeutic approach. Indeed, as mentioned above, CatB seems to 635 
highly support glioma progression and CatD seems to promote invasion of glioblastoma cells 636 
via lysosomal exocytosis [118]. Recent studies investigating CatB inhibition in glioblastoma 637 
have demonstrated encouraging results. CatB/MMP-2-induced invasion in glioblastoma has 638 
been successfully inhibited in vitro by caffeine through the ROCK/FAK/ERK pathway, which 639 
was also accompanied by augmentation of TIMP1 expression [147]. Additionally, CatB was 640 
shown to be a direct target of inhibition by miR140 and this inhibition resulted in decreased 641 
temozolomide-resistance and cell migration in vitro and in vivo [148].  642 
Recently, a study demonstrated that CatD level is upregulated in radioresistant 643 
glioblastoma cells. Inhibition of CatD in those cells led to a decrease in autolysosome formation 644 
and autophagy level, which were associated with increased radiosensitivity. CatD seems to 645 
act on autophagy level by impeding fusion between autophagosomes and lysosomes. This 646 
study revealed that CatD is a promising target in glioblastoma treatment with irradiation [149]. 647 
Interestingly, other lysosomal cysteine cathepsins seem to represent promising targets within 648 
the same context. Glioma cells that undergo irradiation display increased invasiveness and 649 
migration, a phenomenon which represents limitations in clinics. The increased invasion 650 
observed in glioma cell lines undergoing X-ray treatment are accompanied by an augmentation 651 
of CatL level and inhibition of CatL successfully leads to decreased invasion in those cells 652 
[150]. In addition, CatB was recently shown to be the most upregulated protease after 653 
irradiation of glioblastoma cell lines. Its inhibition successfully increased radiosensitivity via 654 
hampering the Homologous Recombination DNA repair system [151]. Finally, inhibition of CatS 655 
is also supported in glioblastoma treatment. CatS inhibition results in induction of autophagy 656 
and apoptosis through inhibition of the PI3K/AKT/mTOR pathway with parallel activation of the 657 
JNK pathway [152]. 658 
A range of cysteine cathepsin inhibitors exists and demonstrates efficacy in many 659 
cancer types, other than glioblastoma [100]. For instance, several small molecule inhibitors 660 
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against CatD have been demonstrated to inhibit proliferation in breast cancer cell lines [153]. 661 
Along the same lines, cathepsin inhibitors could show a promising effect in future glioblastoma 662 
therapeutic trials. Similarly to the other protease families discussed here, cathepsins may also 663 
have putative protective roles in the cancer setting, but the evidence is rare so far. As 664 
discussed earlier, CatG could be a protective protease in glioblastoma [124]; regardless, this 665 
protease is not regarded as a therapeutic target for the time being. 666 
Of note, the levels and regulation of endogenous cathepsin inhibitors seem to have an 667 
impact on cathepsin-mediated glioblastoma cell invasion, which further justifies the use of 668 
synthetized cathepsin inhibitors in glioblastoma patients. For instance, expression of cystatin 669 
C, one of the most potent endogenous cathepsin inhibitors, decreases during glioblastoma 670 
malignant progression. Transfection of cystatin C expression plasmid in glioblastoma cells led 671 
to decreased invasion potential [154]. Along the same lines, in glioblastoma clinical samples, 672 
the endogenous inhibitor stefin B (stefB) is detected in the core of the tumour and not at the 673 
edge where invasion occurs [116]. Additionally, the ratio between cathepsins and StefB is 674 
altered in a spheroid invasion model with the CatB and the CatL-to-stefB ratio higher in the 675 
invading cells [121]. In light of these findings, (re)establishing cathepsin inhibition as a strategy 676 
for glioblastoma treatment appears to be a relevant therapeutic approach.  677 
 678 
Conclusion and future perspectives 679 
Treating glioblastoma remains highly challenging nowadays for several reasons. Firstly, the 680 
blood-brain barrier permeability and tumour cell permeability should be taken into 681 
consideration for any targeted therapeutic approach. This barrier remains a major obstacle in 682 
glioblastoma treatment since it prevents small molecules from reaching the CNS parenchyma, 683 
and also contains active transporters that reject external components. In contrast, the blood-684 
brain barrier in the necrotic core of the tumour is poorly formed and leaky, and thereby, more 685 
permeable. However, the portion located at the edge of the tumour, where invasion occurs, is 686 
quite intact, and typically, fully operational, limiting the capacity of penetration by therapeutic 687 
molecules. Therefore, there is an urgent need for targeted drugs, specifically designed to cross 688 
the intact blood-brain barrier at this microanatomical location [2]. 689 
The second challenge is to find relevant and specific molecular targets to treat 690 
glioblastoma and not normal brain cells or nerves. Under this point of view, targeting proteases 691 
seems to be a promising pharmacological strategy as these molecules are secreted, and are 692 
typically active within the extracellular milieu, implying that targeting these molecules would 693 
not necessarily lead to the suppression of normal healthy cells but instead re-establish a more 694 
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physiological microenvironment. However, many such drugs that simultaneously target 695 
multiple members of these families, have been tested in glioblastoma, and although showing 696 
promise in Phase II, they have failed in Phase III clinical trials [155]. This failure could be 697 
explained in part by the wide targeting spectrum of these inhibitors, as already explained 698 
above. Indeed for example, the non-specific inhibition of multiple MMPs within the glioblastoma 699 
tumour microenvironment could equally target proteases with tumour-promoting and tumour-700 
suppressive properties, thus counter-eliminating any chance of giving beneficial modifications 701 
in the tumour microenvironment during the treatment approach [156]. As such, it is important 702 
to understand the complete biology of these proteases including their impact on invasion at 703 
each step of glioblastoma progression. This would allow us to determine which specific MMPs 704 
should be targeted for the highest clinical benefits. In addition, it is crucial to understand the 705 
physiological roles of these proteases (not necessarily linked to their proteolytic activity), to 706 
avoid chemotherapy-induced side effects. 707 
Extracellular proteolysis is generally constituted as a network of interlinked 708 
mechanisms, usually involving multiple members of the same family, or multiple members from 709 
multiple families, a phenomenon that has been described by many studies as a “proteolytic 710 
cascade”. Therefore, it should be considered that targeting one of them could have a severe 711 
impact on several other proteolytic enzymes that are part of the same cascade of events. For 712 
example, CatB, MMP-9 and uPAR act together in glioblastoma on regulating cell-ECM 713 
adhesion, integrin levels on the surface of tumour and stromal cells, and overall, cell invasion 714 
[112]. In addition, CatB can be activated by CatD and uPAR in addition to an observed auto-715 
catalytic cleavage [102]. uPAR, in turn, converts plasminogen to plasmin, and the latter is 716 
responsible for subsequent MMP activation [43]. To make matters even more complicated, 717 
certain of these MMPs have been shown to not only contribute to the activation of fellow 718 
members of the MMP family, but also to the activation of certain KLK members [84, 157]. A 719 
reverse interplay has also been reported in certain contexts. For example, KLK7 can activate 720 
and produce a specific form of MMP-9 that lacks the Hpx domain [158]. The above described 721 
complexities clearly indicate that obtaining a detailed understanding of the proteolysis 722 
landscape, including the perpetual and looping complexities of the regulatory networks within, 723 
is critical for the development of the most effective and less toxic targeted therapies in glioma, 724 
or glioblastoma. 725 
Finally, there is an urgent need for specific biomarkers in glioblastoma, for better 726 
stratification of patients in personalized medicine and predictive biomarkers for therapeutic 727 
response. As highlighted in this review, most of the MMPs have been shown to be overly 728 
upregulated and/or associated with cancer aggressiveness in glioblastoma, as also have a few 729 
members of the ADAMs/ADAMTS, KLKs, and cathepsins. Among these potential biomarkers 730 
for glioblastoma, studies conducted so far have collectively shown that certain proteases would 731 
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be only relevant as prognostic biomarkers (e.g. MMP-3, KLK7, CatB, see Table 1), while others 732 
would be exclusively useful as diagnostic biomarkers, to help in determining the grade of the 733 
tumour (e.g. MMP-19, ADAM9, ADAM7, CatD, see Table 1). Finally, some are shown to have 734 
potential in both diagnostic and prognostic purposes (e.g. MMP-9, MMP-2, MMP-12, KLK6, 735 
CatS, see Table 1). However, only one of these peptidases, MMP-9, for both liquid and solid 736 
biopsies, may be considered as a validated prognostic biomarker nowadays although is not 737 
yet routinely used to diagnose glioblastoma [39]. The main reason is that this biomarker is not 738 
considered as a therapeutic decision-maker (MGMT promotor methylation state being the only 739 
one widely regarded as such currently). However, the concept of a multi-panel of biomarkers 740 
from liquid and solid biopsies that would represent several peptidases alone or with other 741 
proteins, could serve as a refined prognostic/diagnostic tool for glioblastoma personalized 742 
care.  743 
 744 
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Figure legends 1253 
Figure 1. Classification and structure of peptidase subfamilies involved in glioblastoma 1254 
progression. (A) Subfamily of metzincins, metalloproteinases (MMPs) and transmembrane 1255 
subfamilies of metzincins, adamalysins, comprised of ADAMS and ADAMTS. The MMP 1256 
subfamily is divided into 6 subtypes according to their substrates and their structures: 1257 
collagenases, gelatinases, stromelysins, matrilysins, transmembrane MMP (TM), and other 1258 
MMPs. All MMPs share their catalytic domain (Cat) attached to a zinc atom. Hpx domain = 1259 
Hemopexin domain. Adamalysins are transmembrane proteins that share an MMP domain and 1260 
a disintegrin domain. ADAMTS display thrombospondin domains. (B) Cathepsins B, L, S and 1261 
K belong to the cysteine protease family. Cathepsin D belongs to the aspartic protease 1262 
subfamily. Kallikreins are composed of a (chymo)trypsin domain and belong to the serine 1263 
protease family. 1264 
 1265 
Figure 2. Principal proteolysis-mediated mechanisms of cell proliferation, invasion, and 1266 
angiogenesis in glioblastoma. Glioblastoma and its microenvironment, with central necrotic 1267 
tumour and invasive edge with cells migrating away from the hypoxic centre; foci of proliferative 1268 
glioblastoma cells; and angiogenesis areas with vascular proliferation and new vessel 1269 
formation. (A) Proliferative area with glioblastoma proliferative cells and TAMs. TAMs are 1270 
activated after recognition of glioblastoma cells through their toll-like receptors (TLR), which 1271 
trigger MMP-14 expression, which in turn can activate MMP-2. ADAMs are expressed at the 1272 
surface of glioblastoma cells and release pro-ligands of growth factors into the milieu after 1273 
proteolytic cleavage. Plasminogen is converted into plasmin by the uPAR/uPA complex. 1274 
Plasmin is responsible for MMPs and HGF activation. MMP-2 and -9 are expressed by 1275 
glioblastoma cells, their expression as well as the binding of HGF on its receptor c-Met, and 1276 
the activation of EGFR on glioblastoma cell support cell proliferation. KLK6 cleaves PAR1 in 1277 
glioblastoma cells and mediate intracellular pathways. All the receptors involved (c-MET, uPA, 1278 
PAR1, and EGFR) are upregulated in glioblastoma. (B) Invasive glioblastoma cells (invasive 1279 
edge of the tumour) and mechanisms contributing to cell invasion. The release of lysosomal 1280 
CatD, as well as expression of MMP-2 and -9 by glioblastoma cells contribute to ECM 1281 
degradation. Cell-to-cell and cell-to-matrix interactions are disrupted by MMPs, respectively 1282 
via E-cadherin disruption and CD44-hyaluronic acid disruption. DDR1 and integrin receptors 1283 
interact with collagen. CD44 and DDR1 are upregulated. (C) Angiogenesis mediated by 1284 
proteases in glioblastoma. MMPs are found expressed in vascular proliferation areas, induced 1285 
by angiogenic factors such as Ang-2 and HIF-1. In the extracellular space, MMP-9 controls 1286 
VEGF bioavailability and is responsible for basement membrane disruption, which allows 1287 
endothelial cells to migrate, leading to neo-vessel formation.1288 
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Table 1. Proteolytic enzymes: prognostic/diagnostic value and their implication in glioblastoma progression. 
 
(a) Overexpression in glioblastoma; (b )involvement in glioblastoma progression (invasion, proliferation, angiogenesis); (c) 
Diagnostic value: differential expression between the different glioma grades; (d) Prognostic value: expression associated with 
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